

Harbour BioMed and Sinopharm enter strategic collaboration to establish innovation R&D consortium

July 28, 2026 | News

With a strategic focus on oncology, immune-mediated inflammatory diseases and other therapeutic areas



Harbour BioMed, a US-based biopharmaceutical company, has entered into a strategic collaboration with China National Pharmaceutical Group (Sinopharm). The two parties will establish the Sinopharm - Harbour BioMed Innovation Consortium to advance collaborative research and development of innovative biologics.

Under the terms of the agreement, Harbour BioMed and Sinopharm will collaborate across the full research and development lifecycle of innovative biologics, with a strategic focus on oncology, immune-mediated inflammatory diseases and other therapeutic areas.

Harbour BioMed will leverage its globally leading Harbour Mice[®] fully human antibody technology platform and AI-enabled drug discovery capabilities to drive the discovery and optimisation of antibody candidates together with Sinopharm.

Sinopharm will contribute their expertise in clinical development, large-scale manufacturing and commercialization, and will be responsible for developing commercial-scale manufacturing processes, producing clinical trial materials, and commercialising products arising from the collaboration. The two parties will jointly fund the research and development activities and share product rights in accordance with mutually agreed terms.